^
    CANCER:
    Neuroendocrine Tumor
    TYRO3 mutation + ALK mutation
    Neuroendocrine Tumor
    sunitinib
    Sensitive
    :
    D
    Transl Oncol - 2wk
    TYRO3 mutation + ALK mutation
    Neuroendocrine Tumor
    crizotinib + sunitinib
    Sensitive
    :
    D
    Transl Oncol - 2wk
    TYRO3 mutation + ALK mutation
    Neuroendocrine Tumor
    crizotinib
    Resistant
    :
    D
    Transl Oncol - 2wk
    MSI-H/dMMR
    Neuroendocrine Tumor
    pembrolizumab
    Sensitive
    :
    A2
    NCCN - 3wk
    TMB-H
    Neuroendocrine Tumor
    pembrolizumab
    Sensitive
    :
    A2
    NCCN - 3wk
    No biomarker
    Neuroendocrine Tumor
    surufatinib
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    sunitinib
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    everolimus
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    lanreotide prolonged-release subcutaneous
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    sunitinib
    Sensitive
    :
    A1
    No biomarker
    Neuroendocrine Tumor
    EP
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    octreotide
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    temozolomide
    Sensitive
    :
    A2
    SSTR positive
    Neuroendocrine Tumor
    lanreotide prolonged-release subcutaneous
    Sensitive
    :
    A2
    SSTR positive
    Neuroendocrine Tumor
    octreotide
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    FOLFOX
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    carboplatin + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    temozolomide + capecitabine
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    oxaliplatin
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    dacarbazine
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    cisplatin + etoposide IV
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    nivolumab + ipilimumab
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    pembrolizumab
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    FOLFIRINOX
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    carboplatin + irinotecan
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    cisplatin + irinotecan
    Sensitive
    :
    A2
    No biomarker
    Neuroendocrine Tumor
    FOLFIRI
    Sensitive
    :
    A2
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES